Mepyramine hydrochloride

Synonyms: Pyrilamine hydrochloride
Mepyramine hydrochloride (Pyrilamine hydrochloride) 是一种选择性组胺 H1 受体拮抗剂和 KCNQ 通道抑制剂,对 KCNQ2/Q3 的 IC50 为 12.5 μM,单用时对小鼠过敏性哮喘无活性,但可调节 JNJ 7777120 (MS-O73716) 在小鼠过敏性哮喘中的作用,并能抑制吗啡身体依赖的形成、提高小鼠脑内组胺水平,因此可用于癫痫发作、抽搐、过敏性哮喘及吗啡身体依赖相关研究。
产品编号: MS-T47449 CAS No.: 6036-95-9 分子式: C17H24ClN3O 分子量: 321.84
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Mepyramine hydrochloride (Pyrilamine hydrochloride) 是一种选择性组胺 H1 受体拮抗剂和 KCNQ 通道抑制剂,对 KCNQ2/Q3 的 IC50 为 12.5 μM,单用时对小鼠过敏性哮喘无活性,但可调节 JNJ 7777120 (MS-O73716) 在小鼠过敏性哮喘中的作用,并能抑制吗啡身体依赖的形成、提高小鼠脑内组胺水平,因此可用于癫痫发作、抽搐、过敏性哮喘及吗啡身体依赖相关研究。

生物实验数据

生物活性 Mepyramine hydrochloride (Pyrilamine hydrochloride) is a selective histamine H1 receptor antagonist and KCNQ channel inhibitor with an IC50 of 12.5 μM for KCNQ2/Q3, is inactive against allergic asthma in mice when used alone but modulates the effects of JNJ 7777120 (MS-O73716) in murine allergic asthma, and inhibits the development of morphine physical dependence and elevates brain histamine levels in mice, making it suitable for research on seizures, convulsions, allergic asthma, and morphine physical dependence.
IC50 & Target

H1 Receptor

 

KCNQ2/Q3

12.5 μM (IC50)

体外研究
(In Vitro)


Mepyramine (100 μM) hydrochloride 可强效且可逆地抑制 HEK293 细胞中异源表达的 KCNQ2/Q3 通道,其 IC50 为 12.5 μM,并以电压依赖性方式改变通道门控动力学和电压依赖性激活。
Mepyramine hydrochloride 可抑制 HEK293 细胞中的同源 KCNQ1、KCNQ2、KCNQ3、KCNQ4 通道以及异源 KCNQ3/Q5 通道,且抑制效力存在差异;其中对 KCNQ3/Q5 (IC50 = 4.2 μM) 和 KCNQ3 (IC50 = 9.1 μM) 的活性最强。

体内研究
(In Vivo)

Mepyramine (20 mg/kg;皮下注射) hydrochloride 单独使用对小鼠过敏性哮喘指标的独立影响极小,但会对 JNJ 7777120 (MS-O73716) 的效果产生阶段依赖性调控:在激发期抑制其有益作用,在致敏期增强其有益作用。
Mepyramine (50 mg/kg;腹腔注射;单次) hydrochloride 在 WHT/Ht 小鼠吗啡依赖诱导起始阶段给予时,可抑制吗啡身体依赖性的形成,且不影响吗啡耐受性,同时可使脑内组胺水平升高。

Animal Model: Balb/c (female, 8 weeks old, acclimatized for ≥2 weeks prior to experiments)
Dosage: 20 mg/kg
Administration: s.c.; 30 minutes before each ovalbumin exposure (provocation phase); 30 minutes before and 2 hours after each ovalbumin injection (sensitization phase)
Result: Showed no significant reduction in BAL-fluid eosinophil numbers, no effect on lung tissue inflammatory infiltration scores, and no change in serum anti-OVA IgE, IL-13, or IL-5 concentrations relative to DMSO controls when administered during provocation.
Showed no significant reduction in BAL-fluid eosinophil numbers, reduced lung tissue inflammatory infiltration scores relative to DMSO controls, and no change in serum anti-OVA IgE, IL-13, or IL-5 concentrations relative to DMSO controls when administered during sensitization.
Inhibited JNJ 7777120-induced reductions in BAL-fluid eosinophil numbers and serum anti-OVA IgE concentrations when co-administered during provocation.
Enhanced JNJ 7777120-induced reductions in BAL-fluid eosinophil numbers and lung inflammatory infiltration scores, and significantly reduced serum IL-13 and IL-5 concentrations relative to DMSO controls when co-administered during sensitization.
Animal Model: WHT/Ht (either sex, 25 to 40 g, morphine dependence induced via subcutaneous implantation of 7 mg morphine sulphate-impregnated molecular sieve pellets)
Dosage: 50 mg/kg
Administration: i.p.; single dose
Result: Increased brain histamine levels 24 hours post-treatment: Non-tolerant mepyramine-treated mice had 25% higher brain histamine than non-tolerant controls; tolerant mepyramine-treated mice had 37% higher brain histamine than tolerant controls.
Brain histamine was 16% higher in tolerant mepyramine-treated mice than non-tolerant mepyramine-treated mice.
All increases were statistically significant.

化学信息

分子量 321.84
分子式 C17H24ClN3O
CAS No. 6036-95-9
别名 Pyrilamine hydrochloride

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础